Payment overview · 2025
General Payments
$1,274.94
84 reported records · 13 companies
Healthcare provider profile · identity verified
Sujan Joshi, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROKEN ARROW, OK · NPI 1073741732
Verified facts
What the public records show
CMS Open Payments records show Sujan Joshi, MD received $1,274.94 in general payments during 2025 across 84 reported records.
Novo Nordisk Inc accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.99 | 15.3% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.50 | 14.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.21 | 13.4% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $154.21 | 12.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.04 | 10.8% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.47 | 10.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.83 | 7.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.22 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.90 | 3.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.47 | 2.3% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $29.08 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.41 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,274.94 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $190.50 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $171.21 | 11 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $154.21 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $123.84 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.65 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $92.95 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.24 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.97 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.97 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.86 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.01 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $11.24 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 214 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 136 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 199 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
199 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 180 |
| Lisinopril | Lisinopril | 603 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 160 |
| Losartan Potassium | Losartan Potassium | 510 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 407 | 102 |
| Gabapentin | Gabapentin | 392 | 90 |
| Omeprazole | Omeprazole | 366 | 103 |
| Trazodone Hcl | Trazodone Hcl | 327 | 76 |
| Metformin Hcl | Metformin Hcl | 289 | 87 |
| Simvastatin | Simvastatin | 279 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 61 |
| Buspirone Hcl | Buspirone Hcl | 227 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 220 | 40 |
| Glipizide | Glipizide | 216 | 50 |
| Eliquis | Apixaban | 214 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 81 |
| Ozempic | Semaglutide | 199 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 47 |
| Carvedilol | Carvedilol | 192 | 50 |
| Potassium Chloride | Potassium Chloride | 190 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 56 |
| Sertraline Hcl | Sertraline Hcl | 186 | 35 |
| Meloxicam | Meloxicam | 185 | 47 |
| Montelukast Sodium | Montelukast Sodium | 177 | 46 |
| Methylprednisolone | Methylprednisolone | 175 | 144 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 50 |
| Furosemide | Furosemide | 156 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 26 |
| Baclofen | Baclofen | 151 | 39 |
| Metformin Hcl Er | Metformin Hcl | 141 | 35 |
| Famotidine | Famotidine | 140 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 35 |
| Jardiance | Empagliflozin | 136 | 36 |
| Mounjaro | Tirzepatide | 135 | 23 |
| Farxiga | Dapagliflozin Propanediol | 129 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 22 |
| Temazepam | Temazepam | 110 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 107 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 27 |
| Donepezil Hcl | Donepezil Hcl | 106 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 104 | 16 |
| Alendronate Sodium | Alendronate Sodium | 98 | 25 |
| Memantine Hcl | Memantine Hcl | 98 | 19 |
| Spironolactone | Spironolactone | 97 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 24 |
| Mirtazapine | Mirtazapine | 95 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 24 |
| Celecoxib | Celecoxib | 90 | 20 |
| Pregabalin | Pregabalin | 87 | 11 |
| Atenolol | Atenolol | 86 | 17 |
| Ezetimibe | Ezetimibe | 85 | 22 |
| Finasteride | Finasteride | 85 | 22 |
| Amoxicillin | Amoxicillin | 75 | 61 |
| Glimepiride | Glimepiride | 75 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 22 |
| Allopurinol | Allopurinol | 74 | 23 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | 13 |
| Prednisone | Prednisone | 62 | 44 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | 13 |
| Valsartan | Valsartan | 60 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 23 |
| Naproxen | Naproxen | 53 | 39 |
| Clonidine Hcl | Clonidine Hcl | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 11 |
| Alprazolam | Alprazolam | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Lovastatin | Lovastatin | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 32 |
| Azithromycin | Azithromycin | 43 | 39 |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Chlorthalidone | Chlorthalidone | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 12 |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 27 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 19 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 24 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Torsemide | Torsemide | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xeljanz | Tofacitinib Citrate | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,274.94 · 84 records | Novo Nordisk Inc | AIRSUPRA, Azstarys, CREON, Cologuard Collection Kit, ELIQUIS, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error